8116104

HW

<u>.</u>	3 2004	Rea plus sign (+) inside this box →	+ persons are required	U.S. Patent and Ti	rademark Offi	PTO/SB/21 (05-03) use through 04/30/2003. OMB 0651-0031 ce; U.S. DEPARTMENT OF COMMERCE ss it displays a valid OMB control number.	
BY & TRA	DEMARK		· · · · · · · · · · · · · · · · · · ·	Application Number	10/791,30		
			•	Filing Date	March 1,	2004	
		TRANSMITTAL	_	First Named Inventor	SARVETNICK, NORA		
		FORM		Group Art Unit	1645		
i.		(to be used for all correspondence after in	itial filing)	Examiner Name			
		Total Number of Pages in This Submissi	ion 4	Attorney Docket Number	STEM-00	1CON	
<u>.</u>			ENCLOSUR	ES (check all that apply)			
)		Fee Transmittal Form  Fee Attached  Amendment / Reply  After Final  Affidavits/declaration(s)  Extension of Time Request  Express Abandonment Request  Information Disclosure Statement  Certified Copy of Priority  Documents  Response to Missing Parts/ Incomplete Application	Control   Cont	ing-related Papers  n to Convert to a conal Application of Attorney, Revocation e of Correspondence		After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences  Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)  Proprietary Information  Status Letter  Other Enclosure(s) (please identify below):  Form PTO/SB/08A Postcard	
	(Reg. No	Attorney/Agent PAMELA J. SHER' BOZICEVIC, FIELD e	WOOD, 36,677	ICANT, ATTORNEY, O	R AGENT		
	Date	Auhust 13, 2004					

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**EXPRESS MAIL LABEL NO. EV462737715US** 

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



### Express Mail No. EV462737715US

# INFORMATION DISCLOSURE STATEMENT

Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Attorney Docket	STEM-001CON
First Named Inventor	SARVETNICK, NORA
Application Number	10/791,303
Confirmation No.	3511
Filing Date	March 1, 2004
Group Art Unit	1645
Examiner Name	
1	OR IDENTIFICATION AND DF PANCREATIC ISLET a AND b

**CELL PROGENITORS**"

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and madeforecord.

All of the references identified herein were disclosed in parent application serial number 09/736,911 filed 12/13/2000 and as such, copies thereof are not included pursuant to the provisions of 37 CFR § 1.98(d).

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application with the meaning of 35 U.S.C.§102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. STEM-001CON may be charged thereon.

Respectfully submitted, BOZICEVIC, FIELD & FRANCIS LLP

Date: \_\_\_\_\_August 13, 2004

Pamela J. Sherwood Registration No. 36,677

BOZICEVIC, FIELD & FRANCIS LLP 200 Middlefield Road, Suite 200 Menlo Park, CA 94025

Telephone: (650) 327-3400 Facsimile: (650) 327-3231

PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	e for form 1449A/PTO			d	Complete if Known	
				Application Number	10/791,303	
	INFORMATION DISCL	_os	URE	Filing Date	March 1, 2004	
	STATEMENT BY APP	LIC.	ANT	First Named Inventor	SARVETNICK, NORA	
				Art Unit	1645	
	(use as many sheets as ne	cessa	(v)	Examiner Name		
Sheet	1	of	2	Attorney Docket Number	STEM-001CON	

	U.S. PATENT DOCUMENTS							
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant			
Initials'	No. <sup>1</sup>	Number-Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Figures Appear			
		US- 6,242,666	June 5, 2001	Sarvetnick et al.				
		US- 6,326,201	December 4, 2001	Fung et al.				
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						

		OTHER ART—NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), mublisher, city and/or country where published.	T²
		American Type Culture Collection (1988) p. 173, especially third entry	
		Davidson et al. (1995) "The function and evolution of Msx genes: pointers and paradoxes." TIG, vol. 11(10):405-411	
		Dugan et al. (1997) "HER-2/neu Expression in Pancreatic Adenocarcinoma: Relation to Tumor Differentiation and Survival." Pancreas, vol. 14(3):229-236	
		Graber et al. (1999), "ErbB-4 mRNA Expression is Decreased in Non-Metastatic Pancreatic Cancer." Int. J. Cancer, vol. 84:24-27	
		Gu et al (1993) Epithelial cell proliferation and islet neogenesis in IFN-g transgenic mice. Development, vol. 118:33-46	

	 		_
Examiner	Date		
Signature	Considered		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	te for form 1449B/PTO			Complete if Known		
				Application Number	10/791,303	
	INFORMATION DIS	SCLOS	JRE	Filing Date	March 1, 2004	
	STATEMENT BY A	PPLICA	ANT	First Named Inventor	SARVETNICK, NORA	
				Group Art Unit	1645	
	(use as many sheets a	s necessar	y)	Examiner Name		
Sheet	2	of	2	Attorney Docket Number	STEM-001CON	

		OTHER ART—NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the No. 1 item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s			
		Hall et al. (1990) "The c-erb B-2 Proto-Oncogene in Human Pancreatic Cancer." Journal of Pathology, vol. 161:195-200		
		Kritzik et al. (1999), "PDX-1 and Msx-2 Expression in the Regenerating and Developing Pancreas." Journal of Endocrinology, vol. 163:523-530		
		Kritzik et al. (2000), "Expression of ErbB Receptors During Pancreatic Islet Development and Regrowth." Journal of Endocrinology, vol. 165:67-77		
		LeBras et al. (1998) "A search for tyrosine kinase receptors expressed in the rat embryonic pancreas." Diabetologia, vol. 41:1474-1481		
		Maas et al. (1996) "The Role of Msx Genes in Mammalian Development." Ann. NY Acad. Sci., vol. 785:171-181		
		Oberg-Welsh et al. (1996) "Effects of Certain Growth Factors on In Vitro Maturation of Rat Fetal Islet-like Structures." Pancreas, vol. 12(4):334-339		
	į	Ohlsson et al. (1993), "IPF1, a Homeodomain-Containing Transactivator of the Insulin Gene." EMBO Journal, vol. 12(11):4251-4259		
		Pavelic et al. (1996), "Molecular Genetics of Malignant Insulinoma." Anticancer Research, vol. 16:1707-1718		
		Press et al. (1990) "Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues." Oncogene, vol. 5:953-962		
		Sander et al. (1997) "The .beta. cell transcription factors and development of the pancreas." J. Mol. Med., vol. 75:327-340		
		Sundaresan et al. (1998) "Biological Response to ErbB Ligands in Nontransformed Cell Lines Correlates with a Specific Pattern of Receptor Expression." Endocrinology, vol. 139(12):4756-4764		

Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**DATE: August 13, 2003** 

AU6 1:3 2004

## EV462737715US

# THE EXPRESS MAIL NUMBER OF THE DAY IS: EV462737715US The person taking the Express Mail to the Post Office is: Stuart McLeish

#### **EXPRESS MAIL CERTIFICATION**

<u>Date of Deposit: 08/13/2004</u> I hereby certify that the below-listed papers or fees were inserted into a package addressed to: Commissioner for Patents, PO BOX 1450, Alexandria, Virginia 22313-1450 and was deposited by me with the United States Postal Service "Express Mail Post Office Addressee" service under 37 C.F.R. § 1.10 on the date indicated above.

Signature

Date \_\_\_

Atty. Docket No.	Serial Number	Description	Atty.	Fee
STEM-001CON	10/791,303	Transmittal, IDS, SB08A	PJS	
STAN-270US2	10/729,548	Transmittal, IDS, SB08A, (3) Cited References	PJS	
ABJT-004CON5	10/719,006~	Transmittal, IDS, SB08A	CLF	
DURE- 007CON2	10/719,007	Transmittal, IDS, SB08A	CLF	
STAN-256	10/101,453	Transmittal, Fee Sheet in duplicate, Petition for a 4 Month Extension of Time, Restriction Election	PJS	\$740
STEM-005DIV	10/404,170	Transmittal, IDS, EP Communication dated 07/12/04, (3) Cited References	PJS	
UCLA-004	10/741,292	Transmittal, IDS, SB08A, (5) Cited References	PJS	
IRVN-007DIV	09/562,912	Transmittal, Fee Sheet in duplicate, Communication, Terminal Disclaimer	CLF	
EPIT-003	10/266,387	Transmittal, IDS, SB08A, Copy of International Search dated 08/06/04, (3) Cited References	JSK	
UCAL-263CIP2	10/167,384_	Transmittal, Fee Sheet in duplicate, Amendment (Petition for a 1 Mos Ext of Time)	PAB	\$98
GANG-001	10/259,197	Transmittal, Fee Sheet in duplicate, IDS, SB08A, (1) Cited Reference	CLF	\$180